vs
FTAI Aviation Ltd.（FTAI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
FTAI Aviation Ltd.的季度营收约是Revvity的1.1倍（$830.7M vs $772.1M），FTAI Aviation Ltd.净利率更高（16.2% vs 12.7%，领先3.4%），FTAI Aviation Ltd.同比增速更快（65.5% vs 5.9%），过去两年FTAI Aviation Ltd.的营收复合增速更高（36.8% vs 9.0%）
FTAI航空有限公司是一家全球性航空基础设施及解决方案提供商，主营商用飞机、航空发动机及相关航空资产的持有、租赁与维护业务，为全球商用航空公司、货运运营商提供定制化资产管理及售后支持服务，助力客户提升运营效率。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FTAI vs RVTY — 直观对比
营收规模更大
FTAI
是对方的1.1倍
$772.1M
营收增速更快
FTAI
高出59.6%
5.9%
净利率更高
FTAI
高出3.4%
12.7%
两年增速更快
FTAI
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $830.7M | $772.1M |
| 净利润 | $134.2M | $98.4M |
| 毛利率 | 36.9% | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 16.2% | 12.7% |
| 营收同比 | 65.5% | 5.9% |
| 净利润同比 | 34.7% | 3.9% |
| 每股收益（稀释后） | $1.29 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FTAIRVTY
| Q1 26 | $830.7M | — | ||
| Q4 25 | $662.0M | $772.1M | ||
| Q3 25 | $667.1M | $698.9M | ||
| Q2 25 | $676.2M | $720.3M | ||
| Q1 25 | $502.1M | $664.8M | ||
| Q4 24 | $498.8M | $729.4M | ||
| Q3 24 | $465.8M | $684.0M | ||
| Q2 24 | $443.6M | $691.7M |
净利润FTAIRVTY
| Q1 26 | $134.2M | — | ||
| Q4 25 | $115.6M | $98.4M | ||
| Q3 25 | $117.7M | $46.7M | ||
| Q2 25 | $165.4M | $53.9M | ||
| Q1 25 | $102.4M | $42.2M | ||
| Q4 24 | $102.4M | $94.6M | ||
| Q3 24 | $86.5M | $94.4M | ||
| Q2 24 | $-219.9M | $55.4M |
毛利率FTAIRVTY
| Q1 26 | 36.9% | — | ||
| Q4 25 | 44.3% | — | ||
| Q3 25 | 45.6% | 53.6% | ||
| Q2 25 | 45.4% | 54.5% | ||
| Q1 25 | 50.5% | 56.5% | ||
| Q4 24 | 48.3% | — | ||
| Q3 24 | 52.9% | 56.3% | ||
| Q2 24 | 53.6% | 55.7% |
营业利润率FTAIRVTY
| Q1 26 | — | — | ||
| Q4 25 | 20.3% | 14.5% | ||
| Q3 25 | 21.6% | 11.7% | ||
| Q2 25 | 30.1% | 12.6% | ||
| Q1 25 | 24.9% | 10.9% | ||
| Q4 24 | 21.7% | 16.3% | ||
| Q3 24 | 20.1% | 14.3% | ||
| Q2 24 | -52.5% | 12.4% |
净利率FTAIRVTY
| Q1 26 | 16.2% | — | ||
| Q4 25 | 17.5% | 12.7% | ||
| Q3 25 | 17.6% | 6.7% | ||
| Q2 25 | 24.5% | 7.5% | ||
| Q1 25 | 20.4% | 6.4% | ||
| Q4 24 | 20.5% | 13.0% | ||
| Q3 24 | 18.6% | 13.8% | ||
| Q2 24 | -49.6% | 8.0% |
每股收益（稀释后）FTAIRVTY
| Q1 26 | $1.29 | — | ||
| Q4 25 | $1.06 | $0.86 | ||
| Q3 25 | $1.10 | $0.40 | ||
| Q2 25 | $1.57 | $0.46 | ||
| Q1 25 | $0.87 | $0.35 | ||
| Q4 24 | $0.87 | $0.77 | ||
| Q3 24 | $0.76 | $0.77 | ||
| Q2 24 | $-2.26 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $412.2M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $431.7M | $7.3B |
| 总资产 | $4.5B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FTAIRVTY
| Q1 26 | $412.2M | — | ||
| Q4 25 | $300.5M | $919.9M | ||
| Q3 25 | $509.9M | $931.4M | ||
| Q2 25 | $301.9M | $991.8M | ||
| Q1 25 | $112.1M | $1.1B | ||
| Q4 24 | $115.1M | $1.2B | ||
| Q3 24 | $111.9M | $1.2B | ||
| Q2 24 | $169.5M | $2.0B |
总债务FTAIRVTY
| Q1 26 | — | — | ||
| Q4 25 | $3.4B | — | ||
| Q3 25 | $3.4B | — | ||
| Q2 25 | $3.4B | — | ||
| Q1 25 | $3.6B | — | ||
| Q4 24 | $3.4B | — | ||
| Q3 24 | $3.2B | — | ||
| Q2 24 | $3.1B | — |
股东权益FTAIRVTY
| Q1 26 | $431.7M | — | ||
| Q4 25 | $334.2M | $7.3B | ||
| Q3 25 | $252.5M | $7.4B | ||
| Q2 25 | $164.9M | $7.6B | ||
| Q1 25 | $28.3M | $7.6B | ||
| Q4 24 | $81.4M | $7.7B | ||
| Q3 24 | $118.5M | $7.9B | ||
| Q2 24 | $69.6M | $7.9B |
总资产FTAIRVTY
| Q1 26 | $4.5B | — | ||
| Q4 25 | $4.4B | $12.2B | ||
| Q3 25 | $4.2B | $12.1B | ||
| Q2 25 | $4.1B | $12.4B | ||
| Q1 25 | $4.3B | $12.4B | ||
| Q4 24 | $4.0B | $12.4B | ||
| Q3 24 | $3.7B | $12.8B | ||
| Q2 24 | $3.4B | $13.4B |
负债/权益比FTAIRVTY
| Q1 26 | — | — | ||
| Q4 25 | 10.32× | — | ||
| Q3 25 | 13.65× | — | ||
| Q2 25 | 20.88× | — | ||
| Q1 25 | 128.56× | — | ||
| Q4 24 | 42.28× | — | ||
| Q3 24 | 27.15× | — | ||
| Q2 24 | 44.24× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流FTAIRVTY
| Q1 26 | — | — | ||
| Q4 25 | $-179.1M | $182.0M | ||
| Q3 25 | $4.6M | $138.5M | ||
| Q2 25 | $-110.3M | $134.3M | ||
| Q1 25 | $-26.0M | $128.2M | ||
| Q4 24 | $-41.8M | $174.2M | ||
| Q3 24 | $41.5M | $147.9M | ||
| Q2 24 | $-187.3M | $158.6M |
自由现金流FTAIRVTY
| Q1 26 | — | — | ||
| Q4 25 | $-189.3M | $161.8M | ||
| Q3 25 | $-1.8M | $120.0M | ||
| Q2 25 | $-117.2M | $115.5M | ||
| Q1 25 | $-30.1M | $112.2M | ||
| Q4 24 | $-48.1M | $149.8M | ||
| Q3 24 | $41.0M | $125.6M | ||
| Q2 24 | $-188.4M | $136.6M |
自由现金流率FTAIRVTY
| Q1 26 | — | — | ||
| Q4 25 | -28.6% | 21.0% | ||
| Q3 25 | -0.3% | 17.2% | ||
| Q2 25 | -17.3% | 16.0% | ||
| Q1 25 | -6.0% | 16.9% | ||
| Q4 24 | -9.6% | 20.5% | ||
| Q3 24 | 8.8% | 18.4% | ||
| Q2 24 | -42.5% | 19.7% |
资本支出强度FTAIRVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.5% | 2.6% | ||
| Q3 25 | 1.0% | 2.6% | ||
| Q2 25 | 1.0% | 2.6% | ||
| Q1 25 | 0.8% | 2.4% | ||
| Q4 24 | 1.3% | 3.4% | ||
| Q3 24 | 0.1% | 3.3% | ||
| Q2 24 | 0.3% | 3.2% |
现金转化率FTAIRVTY
| Q1 26 | — | — | ||
| Q4 25 | -1.55× | 1.85× | ||
| Q3 25 | 0.04× | 2.97× | ||
| Q2 25 | -0.67× | 2.49× | ||
| Q1 25 | -0.25× | 3.03× | ||
| Q4 24 | -0.41× | 1.84× | ||
| Q3 24 | 0.48× | 1.57× | ||
| Q2 24 | — | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FTAI
| Aerospace products revenue | $522.6M | 63% |
| MRE Contract revenue | $221.2M | 27% |
| Lease income | $39.9M | 5% |
| Maintenance revenue | $30.6M | 4% |
| Asset sales revenue | $10.2M | 1% |
| Other revenue (1) | $6.2M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
